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1078–5Objectives. The scientific quality of published clinical trials is generally poor in studies where compression devices have
been assessed in the management of venous disease. The authors’ aim was to establish a set of guidelines which could be
used in the design of future clinical trials of compression treatments for venous diseases.
Design. Consensus conference leading to a consensus statement.
Methods. The authors form a expert consensus group known as the International Compression Club (ICC). This group
obtained published medical literature in the field of compression treatment in venous disease by searching medical literature
databases. The literature was studied by the group which attended a consensus meeting. A draft document was circulated to
ICC members and revised until agreement between contributors was reached.
Results. The authors have prepared a set of guidelines which should be given consideration when conducting studies to
assess the efficacy of compression in venous disease.
Conclusions. The form of compression therapy including the comparators used in the clinical study must be clearly char-
acterised. In future studies the characteristics of the material provided by the manufacturer should be described including in
vivo data on pressure and stiffness of the final compression system. The pressure exerted on the distal lower leg should be
stated in mmHg and the method of pressure determination must be quoted.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
Keywords: Compression devices; Clinical studies; Guidelines; Venous disorders; International compression club.Introduction
The level of clinical trials in which compression de-
vices are used to treated venous disease is frequently
poor,1,2 with lack of standardisation in methodology
and measurement. It is desirable to develop a set of
guidelines for clinical trials with compression devices
In order to ensure a consistent approach in design and
reporting of data. Currently no guidelines have been
published either on a national or an international
level.sponding author. Dr E. Rabe, University Department of Der-
gy, Sigmund Freud Str. 25, D- Bonn, Germany 53105,
ny.
address: pielhau@vr-web.de
884/000494+ 07 $34.00/0  2007 Published by Elsevier Ltd onMethods
These guidelines were prepared by a group of distin-
guished experts each of whom has published scien-
tific work in the field of venous disease (Table 1).
This group refers to its members as the ‘International
Compression Club (ICC). Published papers relevant
to these guidelines are identified from searching the
medical literature databases Medline and Embase,
and on the UIP-consensus on evidence-based com-
pression-therapy.2 The meeting of the ICC at which
the first draft of the guidelines was discussed took
place in Cologne the 17th September 2005. The results
of this discussion were included in a further draft
which was then sent by e-mail to the experts of the
group for further comment. Further versions of the
document were circulated to the group untilbehalf of European Society for Vascular Surgery.
Table 1. Members of the International Committee who agreed
with the consensus statement
M. Abel, Germany CH. Moffat, UK
I. Achhammer, France F. Pannier, Germany
A. Andriessen, Netherlands H. Partsch, Austria
F. Becker, France K. Peters, UK
D. Bender, USA E. Rabe, Germany
J-P. Benigni, France A.A. Ramelet, Switzerland
J-C. Bouvier, France H. Schepers, Switzerland
A. Cornu-Thenard, France J. Schuren, The Netherlands
C. Feenstra, Netherlands M. Spengler, Germany
J. Greve, Germany U. Schettler, Germany
J. Hutchinson, UK K. Tucker, Germany
K. Ißberner, Germany J. F. Uhl, France
M. Ju¨nger, Germany W. Vanscheidt, Germany
D. Kolbach, Netherlands P. Zo¨llner, Germany
Table 2. Requirements for a study-protocol
 Background of the study (literature review and risk management
assessment),
 primary (and if applicable secondary) objective(s),
 the design (controlled, open, randomized, multi-centre etc.),
 the population (detailed description of the disease, inclusion and
exclusion criteria),
 duration of the study and/or treatment,
 number of visits and interventions at the different visits (study
flow chart),
 detailed description of the treatment and comparator or control,
 primary and secondary outcome parameters,
 statistical planning of evaluation and sample size calculation.
 additional documents or approvals include patient information
and consent forms, ethics committee statement, case report
forms, patient insurance,
 the Declaration of Helsinki, and a list of references
495Guidelines for Clinical Studies with Compression Devices in Venous Disordersagreement of all members was obtained. The resulting
text appears below.General, legal and formal aspects
Studies must be planned, conducted and evaluated
according to current directives and guidelines, exam-
ples of which are given at the end of this chap-
ter.3,4,5,6,7 It is a legal requirement to follow local or
national laws concerning the conduct of clinical trials,
and this takes precedence over international guide-
lines. As differing directives and guidelines may ap-
ply in different countries, investigators must ensure
that the relevant national instructions are taken into
account. It is recognised that directives and guidelines
change, so it is important to ensure that the most
recent version of these documents is identified and
used.
In order to conduct a clinical trial of the efficacy
and safety of a treatment or method with uncertified
medical devices, approved medical devices or han-
dling instructions used in off-label indications or
with additional unusual burdens for the patient,
a study protocol with all additional necessary docu-
ments or approvals must be prepared. The items
that must be clearly described are listed in Table 2.
Registration with or approval by the relevant na-
tional authorities may be necessary depending on
the national or local law.
The results of the study should be summarised in
a clinical, biometric report containing critical com-
ments on the study concept, the study methodology
and interpretation of the results, and take into account
the clinical and scientific knowledge available. The
report should draw conclusions for the medical pro-
fession, the medical device manufacturer and, where
appropriate, the health authorities and any other bod-
ies. This comprehensive report constitutes part of theclinical trial and is necessary regardless of whether or
not the study is to be published. The conduct of clin-
ical studies with certified medical devices used in
their certified indications or ‘instructions for use’ are
governed by minor regulatory requirements e also
dependent on the current national or local law.
Examples of directives and guideline and internet
URLs:
- ICH (International Conference of Harmonisation)
e.g. Topic E 6: Guideline for Good Clinical Practice
in the European Community. (www.ich.org)
- DIN ISO EN 14155-1/-2: ‘Clinical investigation of
medical devices for human subjects e Part 1: Gen-
eral requirements’. Part 2: Clinical investigation
plans’ (edited by Beuth Verlag, www.beuth.de)
- MEDDEV 2,12e2 May 2004 ‘Guidelines on post
market clinical follow-up’. (http://europa.eu.int/
comm/enterprise/medical_devices/meddev/)
- MEDDEV 2.7.1. Clinical investigation, clinical
evaluation, Guide for manufacturers and notified
bodies
General comments on the classification of chronic
venous disorders
The CEAP classification system for chronic venous
disorders takes into account clinical, etiological,
anatomical and pathophysiological factors. Its infor-
mative value has been validated. We therefore recom-
mend that patients with chronic venous diseases be
classified according to their CEAP classification for
future studies. In addition, the CEAP classification
system offers a limited assessment of changes in the
clinical scoring system.8 The use of the Basic CEAP
classification is mandatory.8
For studies that require greater patient differentia-
tion the Scientific CEAP classification is recommended.8
However, since CEAP is mainly a descriptiveEur J Vasc Endovasc Surg Vol 35, April 2008
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to assess the outcome after therapy (e.g. Venous sever-
ity scoring VSS).9
In studies on patients with acute venous diseases
the classification must include exact localisation,
extent and duration of the changes.Requirements
1 Principal requirements
The form of compression therapy including the
comparator(s) used in the clinical study must be
characterized.Medical compression garments
The following data should be given:
 type and size of the compression garment (calf,
thigh)
 the kind of material, flat or round knitted
 the pressure range at ankle level (mm Hg, measur-
ing method), pressure according to manufacturer’s
labelling
 the pressure gradient
 Ready to wear or made to measure
The following data should be encouraged:
 Slope/stiffness of the material
 In vivo pressure values
The compression garment used must be marked
(e.g. with a code) to ensure that the same garment is
used during the study.Compression bandages
The following data should be given:
 Material, number and type of components
 Size (length with and without stretch, width) of
the bandage (if measured with stretch the percent-
age of stretch needs to be given)
 Length of the bandage system (calf, thigh)
 Technique of application (spiral, figure-of eight,
overlap)
The following data should be encouraged:
 Stiffness of the final bandage (system)
 In vivo pressure valuesEur J Vasc Endovasc Surg Vol 35, April 2008The size of the ankle should be recorded in all tri-
als. This ensures that the correct choice of bandages
is made for all patients. While most ankle sizes range
from 20 to 25 cm there is a proportion with very small
and large limbs.
Pumps and other mechanical devices




B Inflation and deflation characteristics
B Duration
B Number
In comparative trials the above-mentioned character-
istics should be declared for all compression devices
tested or used.2 Further requirements
The following points should be considered depending
on the details of the study:
Material
The declaration of fibre content, extensibility in longi-
tudinal and transverse direction and of stiffness
(hysteresis-curve) are desirable (see above).
The influence exerted by the compression product
on resting and working pressures depends upon the
extensibility of compression material. The elastic
properties of a compression bandage or system are af-
fected by the number of layers in the system, whereby
the greater the number of layers, the greater the effect.
Details on the number and nature of layers must be
provided.
In future studies the characteristics of the material
provided by the manufacturer should be declared in-
cluding the in vivo data on pressure and on stiffness of
the final compression system on the individual leg.10
It has to be declared whether bandages have been
washed or not.
Person applying the compression device
Compression trials are very user dependant. Every at-
tempt should be made to limit the number of people
applying the bandages within a trial as considerable
variation occurs between experienced bandagers. All
personnel involved in applying bandages (patient,
relatives, medical staff) should have a formal stan-
dardized training which includes pressure measure-
ments of their technique.
497Guidelines for Clinical Studies with Compression Devices in Venous DisordersDuration of compression and concordance
The time of compression per day and the total wear
time must be noted and patients’ concordance must
be documented.
Concordance where possible should be recorded by
the patient and assessed by a blinded assessor to
avoid the temptation of labelling ‘‘deviant‘‘ patients.Previous compression therapy
What kind and for how long.Durability and costs
Durability, reusability and costs of the material should
be described where applicable.Cost-effectiveness
Cost-effectiveness evaluation is desirable in clinical
studies depending on the size and nature of the study.
There is a wide range of possible analyses including
cost minimisation, cost reduction, cost-benefit relation
etc. Clinical trials should aim to measure cost effec-
tiveness which allows both clinical and cost outcomes
to be considered together.Physical activity
Physical activity and walking ability of the patient
(ADL¼Activities of daily living) should be de-
scribed. The daily walking distance or activity may
be measured using a pedometer.
Validated tools for measuring activities of daily liv-
ing are recommended. Independent risk factors for ul-
cer healing have been identified, like general mobility
status (chair/bedbound, walking outside unaided,
walking inside aided and walking freely) and ankle
function (full movement, reduced ankle function,
fixed ankle joint).Quality of life
Patient reported outcome (PRO) and Quality of life
(QoL). Validated, disease-specific and generic Quality
of life questionnaires should be used.11,12,13,14Table 3. Compression classes of compression hosiery used in severa
Compression Class USA UK
I 15e20 (moderate) 14e
II 20e30 (firm) 18e
III 30e40 (extra firm) 25e
IV 40þ
The values indicate the compression exerted by the hosiery at a hypoPressure
The pressure exerted on the distal lower leg should
be given in mmHg and the method of pressure
determination must be quoted. Report of in vivo
pressure using a pressure sensor specific to a manu-
facturer is not recommended. Compression classes
vary considerably between different countries
(Table 3).
In order to find a clear and internationally acceptable
languagewe propose to replace compression classes by
pressure ranges at the ankle region, declaring the in
vitro-method of measurement: e. g. 10e20 mmHg,
20e30 mmHg, 30e40 mmHg, >40 mmHg.
The pressure values given by the manufacturers of
medical compression hosiery are measured by differ-
ent methods (e.g. ITF, HOSY, HATRA). For future tri-
als the additional measurement of in vivo pressure is
encouraged.
Several instruments are available for measuring the
in vivo -pressure exerted by compression garments on
patients’ limbs.15,16 Recommendations as to how and
where the pressure should be measured have been
proposed by the ICC.17 Several important points
have to be considered (Table 4).
It is recommended that any pressure sensor that is
considered for use should satisfy, or come close to, the
following key specifications:17
 The sensor should be thin and flexible. Based on
theoretical model calculations that are mainly
valid for flat areas a maximal sensor thickness of
0.5 mm is suggested.
 The sensitive area of the sensor should be adjust-
able and optimized for different applications
(leg, hand, toe) and different measuring regimes:
e. g. small areas for mapping of a circumferential
pressure pattern, large sensor areas (over 5 cm2)
for measuring the integral pressure of a larger
area taking advantage of the fact that the local
pressure distribution will be averaged over chang-
ing curvatures of the leg segment.
 The sensor should be able to be left in contact with
the leg for extended periods of time without skin
irritation and should keep its accuracy.l countries. (Values in mmHg, 1 mmHg[ 1,333 hPa)
(BS 6612) France Germany
17 (light) 10e15 18e21 (light)
24 (medium) 15e20 23e32 (medium)
35 (strong) 20e36 34e46 (strong)
>36 >49 (very strong)
thetical cylindrical ankle.
Eur J Vasc Endovasc Surg Vol 35, April 2008
Table 4. Measurement of sub-bandage pressure is influenced by several factors
Pressure Sensors Site of sensor Application Method of Application Position of limb
Small diameter sensors tend
to report peak pressures
Sensor placed over soft tissue or flat
parts of the leg may show lower
pressures than when placed on a
hard area or on curved parts




high readings due to lack
of conformability
Figures of eight or Spiral
Number of layers
Degree of overlap
498 E. Rabe et al. Pressure measurement systems that allow contin-
uous pressure measurement during active or pas-
sive patient movement (e.g. muscle pump test or
tilt test) are preferred.
 Easy sensor calibration conducted ideally before
each measurement.
 Multiple sensors allowing concurrent measure-
ment of pressures under the device at several
anatomical sites may be preferred over single
sensors.Methods of Measurement
Parameters and methods
Many parameters and methods are applicable for
measuring a variety of compression effects (Table 5).
This does not mean that all methods should be used
together in future trials. Methods should be selected
according to the specific objective of the study.
For any vein diameter or any haemodynamic
parameter the position must be specified (supine
position, sitting position, standing position on both
feet or on contralateral foot).Table 5. Parameters and methods
Endpoint Methodology
Vein diameter ultrasound, phlebography
Venous compliance pressure/volume relationship using si
Lympatic drainage lymphoscintigraphy, fluorescence micr
intralymphatic pressure measurement
Leg volume water displacement volumetry, ultraso
photography, other validated methods
Microcirculation laser Doppler fluxmetry (to assess the




efficacy parameters, effects on the freq
Recanalisation of a vein duplex, measurement of outflow fracti
assessment of refluxes by measuring v
Lipodermatosclerotic
skin changes
skin thickness with high frequency ult
tissue compliance monitor18,19
Ulcer healing incidence of complete healing, area-pla
per unit time with correction for ulcer
a: start and b: end of the observation],
patients, including those lost to follow
Clinical parameters symptoms on analogue scale including
Eur J Vasc Endovasc Surg Vol 35, April 2008Definition of the level of arterial disease, an ABPI of
0.8 or above can be accepted.
In ulcer trials risk factors that affect healing rates
should be documented, e. g. Body Mass Index
(BMI). At least ulcer size and ulcer duration, which
are the two most important predictive factors.Examples for outcome parameters in future
compression studies
The outcome parameters used and presented should
be selected according to the different stages of chronic
venous diseases included in trials (Table 6). All
methods used for clinical studies must be validated.
In all CEAP stages, quality of life, standardized eval-
uation of patients’ satisfaction, venous severity scor-
ing, changes in CEAP-classification, and VAS for
subjective complaints should be used. In all stages
compliance with compression must be documented.
For standardized photodocumentation, assessment
by blinded observers is preferred. Long term assess-
ment is preferred in all stages although it is recog-
nised that this may not always be feasible. (Table 6)multaneous measurements of venous pressure and of volume
olymphoangiography, indirect x-ray lymphography,
und, optoelectonic instruments, computerized digital
veno-arteriolar reflex and vasomotor activity),
roscopy, skin biopsy
uency of side effects like phlebitis, pigmentation, bruising, pain etc
on by strain gauge or air plethysmography (APG), quantitative
enous filling index (ml(sec) using APG
rasound (e.g. 20 MHz), CT, NMR, by the durometer,
nimetry, area in cm2  p/4 (ellipse), Gillman method healing rate
size (AbAa)/(Paþ Pb)/2) (ba) [A: area of ulcer, P: perimeter,
time to complete healing, life table analysis should include all
up and treatment failures20
pain, CEAP, classification and VSS, QoL
Table 6. Examples for specific outcome parameters in different stages of VD
Disease C of CEAP Outcome Parameters
Subjective symptoms without clinical signs C0, S occurrence rate and severity of symptoms
Teleangiectases, reticular veins, symptomatic C1, S visual analogue scale (VAS) for the subjective complaints
Small varicose veins after sclerotherapy or
laser treatment
C1 clinical improvement type and frequency of complications
Large varicose veins, asymptomatic C2, A frequency of clinical progression and complications occurrence of
subjective complaints
Large varicose veins, symptomatic C2, S VAS for subjective complaints frequency of clinical progression and
complications
Large varicose veins in pregnancy C2, A, S frequency of clinical course (progression/regression) and complication
occurrence of subjective complaints, venous diameter and reflux
Large varicose veins after surgery,
sclerotherapy, endovenous laser or
radiofrequency treatment
C2eC6 clinical improvement frequency of complications occlusion rate, reflux
recurrence rate
Venous oedema (including postthrombotic
oedema and oedema in angiodysplasias)
C3 measurement of volume changes by: standardized circumference
measurements volumetry (water displacement, optoelectronic, digital
cameraþcomputer)
Skin changes (eczema, pigmentation) C4a eczema score thermography, colorimetry
Skin changes (lipodermatosclerosis,
white atrophy)
C4b rate of progression and improvement durometer, ultrasound B-scan
(thickness and texture), CT, NMR, thermography
Healed ulcer C5 rate of ulcer recurrence (at the site of ulcer, a new area of ulceration on
the same limb and contra lateral limb)
Active ulcer C6 rate of ulcer-healing, healing-time. (Detailed wound documentation with
description of different wound parameters over the treatment period and
follow-up phase.)
Prevention of venous thromboembolism DVT-rate pulmonary embolism-rate superficial phlebitis-rate
Superficial phlebitis improvement of symptoms (e.g. pain) and signs (inflammation)
assessment
of thrombus extension in superficial and/or deep veins, occurrence of
pulmonary emboli
Deep vein thrombosis (DVT), early onset change of thrombus size symptoms (pain) oedema formation occurrence
of pulmonary emboli (repeated V/Q-scans) DVT-recurrence (rate), death
occurrence of post-thrombotic syndrome (rate, time)
Prevention of post-thrombotic syndrome (PTS)
after DVT
DVT-recurrence (rate), death subjective symptoms (pain, heaviness)
oedema formation (leg volume) skin changes reflux/occlusion (rate)
499Guidelines for Clinical Studies with Compression Devices in Venous DisordersEstablishing a reliable diagnosis of chronic venous
disorders and acute venous diseases
It must be reliably determined that the clinical find-
ings in each study subject are the result of a distur-
bance of venous haemodynamics. A clinical
examination is not sufficient to do this.
The clinical picture as well as the pathological
changes need to be specified using imaging and func-
tional methods:
Imagingmethods include duplex sonography, phle-
bographyorMRIwhich canbeused to localise avenous
disorder in the sub- and extra-fascial venous system.
Functionalmethods include duplex andDoppler so-
nography to demonstrate reflux in the superficial and/
or deep veins. Phlebodynamometry (measurement of
intravenous pressure) is currently to be regarded as
the reference procedure to record venous pumping ac-
tion. Alternative methods include various forms of
plethysmography such as the strain gauge method,
foot volumetry and photoplethysmographic methods.
Acute venous diseases must be documented
and classified by imaging methods (e.g. duplex,
phlebography).Study Criteria
1 Inclusion criteria
B Signed informed consent declaration/data protec-
tion declaration
B Exact diagnosis based on the CEAP classification2 Precautions
The following points which may be exclusion criteria
should be carefully considered
B Diseases/symptoms that imitate the symptom-
atology of venous disease (e.g. lymphoedema,
lipoedema)
B Heart failure
B Severe renal and hepatic failure
B Competing/interfering, concomitant systemic and
local drug treatments (no newly startedmedication
with a vascular or cardiovascular effect should be
taken/administered during the treatment)
B Known allergies to the compression materialEur J Vasc Endovasc Surg Vol 35, April 2008
500 E. Rabe et al.B Patients who have already taken part in another
study with the same objective up to 3 months
before entering this study
B Patients who have already taken part in the study
B Asymptomatic and symptomatic peripheral occlu-
sive arterial disease, malleolar artery pressure
values with a reduced ankle/arm index (<0.8) (if
not indicated in the designed study population,
e.g. mixed leg ulcers)
B Limited mobility of the study leg (e.g. paralysis) if
not part of the study design3 Concomitant treatment
Continued treatment of other diseases is allowable de-
pending on the test parameters chosen, andwith the pro-
viso that the treatment will not interfere with the trial
outcome.Anyconcomitantmedicationmustbe recorded.4 Withdrawal criteria
B Deterioration in the clinical picture of venous dis-
orders (e.g. progression to a higher stage of CVI) if
not indicated in the designed study population
B Lack of concordance by the patient
B Withdrawal of patients consent (reasons for with-
drawal of patient consent should be documented)
B Change in measures and events that affect the tar-
get criteria Example: Initiation, change or discon-
tinuation of hormone therapy, diuretic treatment
B Intercurrent infections of the lower extremityPerspective
The present recommendations for testing the thera-
peutic efficacy of compression treatments in patients
with venous disorders are designed to help to deter-
mine the significance of the various treatment modal-
ities more accurately and consistently by means of
qualified clinical studies.Acknowledgments
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